Oncoinvent Update

Oncoinvent would like to extend an invitation to a short update on the company. The presentation will be held on Friday 17. February 2023 at 09:00 AM in the company offices at Gullhaugsveien 7, Oslo, 3rd Floor. It will also be possible to attend virtually.

To attend, please register with kvam@oncoinvent.com.


Oncoinvent ønsker med dette å invitere til en kort status oppdatering. Presentasjonen vil holdes Fredag 17. februar 2023, kl. 09:00 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje. Det vil også være mulig å delta virtuelt.

Vi ber om at deltakere registrerer seg ved å sende en e-post til kvam@oncoinvent.com.

Organiser: Oncoinvent

Gullhaugveien 7, Oslo / Virtual

Date: 17 February 2023

Jan Alan Alfheim

Chief Executive Officer


+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.